Skip to content

Inspection Record

LeeSar Inc — FDA 483 Findings

US FDAInspected 2026-09-23Published 2026-11-05 9 findingsEquipment and facilityAseptic processing and sterility assuranceLaboratory and QC controlsQuality unit oversightStability and storageLabeling and packaging

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

3Laboratory and QC controls

The accuracy, sensitivity, specificity, reproducibility of test methods have not been established and documented.

4Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

5Stability and storage

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

6Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

7Labeling and packaging

Samples of representative units were not visually examined for correct labeling at the completion of finishing operations.

8Equipment and facility

The persons double-checking the cleaning and maintenance are not dating, signing or initialing the equipment cleaning and use log.

9Equipment and facility

Written procedures are not established or followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

LeeSar Inc findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.